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GCP accreditation – a worthwhile 
investment?
To the Editor: The exponential increase in the clinical trial 
industry, especially in developing countries, has been well 
publicised.1-3 Subjects in these countries are particularly 
vulnerable, most notably because of limited economic 
development, inadequate human rights, an insufficient 
understanding of scientific research and limited health care 
treatment.3,4 Recent reports estimate that clinical trials in 
South Africa generate in excess of one billion rand annually.5 
It is therefore not surprising that clinical trials are susceptible 
to unethical practices and even to the occasional instance of 
scientific fraud. The growth in the clinical trial industry has 
resulted in the development of a new medical subspecialty, 
commonly referred to as research medicine. However, this is 
the only specialty where formalised specialised training or 
proven expertise is not required.1
   When investigators sign the FDA 1572 form (Statement of 
the Investigator), they are certifying that they are qualified 
to conduct all aspects of the clinical trial. With no standard 
method of assessing whether the investigator is actually 
qualified, a certification process may be of value. The idea of 
investigator certification programmes is not new and there are 
now four organisations in the USA offering such certification.1
   The Medicines Control Council (MCC) has recently made 
training in Good Clinical Practice (GCP) mandatory for all 
investigators. GCP is an international ethical and scientific 
quality standard for designing, conducting, recording and 
reporting trials that involve the participation of human 
subjects. The guidelines represent the ethical principles 
embodied in the World Medical Association Declaration of 
Helsinki (formulated June 1965, updated October 2000). Ethics 
committees are likewise demanding similar training.
   There are, however, currently no accreditation and/or 
standardisation guidelines for such training. This has resulted 
in a plethora of training courses, often at substantial costs, 
being offered by various institutions. They typically run 
over 2 - 3 days, with shorter refresher courses offered as 
updates. Time constraints of investigators have resulted in 
these courses being shortened considerably at the expense of 
course content. In some cases, the qualifications and/or the 
expertise of providers is also questionable. Faced with a similar 
predicament, the European Union (EU) has issued a directive 
(Clinical Trials Directive 2001/20/EC) and a syllabus for 
training clinical investigators.6 
   To ensure continued investment and growth in this profitable 
area, South Africa (like the EU) needs to implement structures 
that will ensure a certain level of professionalism in the local 
clinical trial industry. Insisting on GCP accreditation is a sure 
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way to guarantee research integrity and offer investors a 
worthwhile return on their money.
Lesley J Burgess 
Nicky U Sulzer
TREAD Research/Cardiology Unit
Tygerberg Hospital and Stellenbosch University
Tygerberg, W Cape
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NoAH rescues AIDS orphans
To the Editor: Wim Delva et al.1 are to be thanked for raising 
the issue of the orphan epidemic that is the eventual (perhaps 
inevitable) consequence of the AIDS pandemic.
   It is quite possible that our attempts to reduce the numbers 
of orphans by treating their parents will fail. In fact it is 
probable that we will not reduce the numbers of children being 
orphaned, at least not in a socially meaningful way. Even if 
there were no further deaths from AIDS, we already have over 
a million orphans in South Africa alone. Currently around 19 
children are orphaned because of AIDS deaths each hour.
   It was for exactly the reasons set out in that article1 that we 
began an NGO with the aim of addressing this challenge on a 
scale that might be meaningful to the country. That was in  
2000/2001.
   We are called NOAH (Nurturing Orphans of AIDS for 
Humanity). Our view is that it is simply wrong to begin any 
strategy that is so expensive (in terms of money or manpower) 
that it cannot be rolled out on a large scale. The pool of 
resources is small and any expensive plan for children in one 
place simply robs resources from children elsewhere. 
   We try to build networks that care for orphans within 
their own communities. These consist of three fundamental 
elements: (i) a committee of community leaders to control 
the programme and motivate the community; (ii) a volunteer 
group trained in counselling to visit orphans at home and 
to check on their wellbeing (home circumstances, school 
attendance, etc.), reporting back to the social worker; and (iii) 
a resource centre that acts as a day care and aftercare centre to 
unburden caregivers at home by having orphans occupied (in a 
positive and safe place) all day and fed when they arrive home.
   We believe that these elements constitute a core of support 
that is sustainable and that can be extended throughout South 
Africa. We are currently working in 68 communities with the 
support of corporate South Africa, our government and the 
US PEPFAR programme. The support of everyone approached 
has been typically South African. From the top businessmen 
we asked to give of their time to serve on our board to 
unemployed rural volunteers, South Africans are standing up 
to meet this challenge. 
   We know of other excellent NGOs such as Heartbeat and 
Hands at Work that are providing support using similar 
models. 
   Given the high levels of unemployment and the lack of 
skilled people in South Africa it is essential that all of us ‘do 
our bit’ if we are to raise these children to be whole adults. 
The consequences of inaction or apathy are too horrible to 
contemplate.
   I encourage all of my colleagues to find orphan initiatives 
near their homes (local is sustainable and orphans are 
everywhere, in every community) and see what they can do 
to help. Whether your skills lie in working with the children 
or helping with the bookkeeping is not important, there is 
something everyone can do.
   You can find out more about NOAH at Noahorphans.org.za
Greg Ash
Vice Chairman, NOAH
Private Bag X01
Umhlanga
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